A M Tsimberidou

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
  2. ncbi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
  3. ncbi Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 71:389-97. 2013
  4. ncbi Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
  5. ncbi Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression
    Christos Vaklavas
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Virol J 7:256. 2010
  6. ncbi Richter's transformation in chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:250-6. 2006
  7. ncbi Treatment of fludarabine-refractory chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2824-36. 2009
  8. ncbi Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
    Apostolia Maria Tsimberidou
    Department of Leukemia, Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2343-51. 2006
  9. ncbi Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leuk Lymphoma 47:1062-8. 2006
  10. ncbi Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009

Detail Information

Publications59

  1. ncbi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  2. ncbi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS...
  3. ncbi Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 71:389-97. 2013
    ..Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients...
  4. ncbi Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
    ..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis...
  5. ncbi Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression
    Christos Vaklavas
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Virol J 7:256. 2010
    ..Extensive investigation for an occult immunocompromising disorder was negative. The patient's neurologic deficits rapidly increased throughout his hospital stay, and he died 3.5 months after his diagnosis...
  6. ncbi Richter's transformation in chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:250-6. 2006
    ....
  7. ncbi Treatment of fludarabine-refractory chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2824-36. 2009
    ..In conclusion, chemoimmunotherapy regimens that include alemtuzumab and/or rituximab and allogeneic stem cell transplantation improve the prognosis of this disease, but there is a continued need for novel, more effective therapies...
  8. ncbi Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
    Apostolia Maria Tsimberidou
    Department of Leukemia, Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2343-51. 2006
    ..The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival...
  9. ncbi Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leuk Lymphoma 47:1062-8. 2006
    ..The observation that patients can be cured of APL without the use of chemotherapy should encourage further study of 'targeted' therapy in APL and in other leukemias...
  10. ncbi Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009
    ..Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed...
  11. ncbi Richter syndrome: biology, incidence, and therapeutic strategies
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:216-28. 2005
    ..In conclusion, RS may be triggered by viral infections or by genetic defects. Current treatments are aggressive, but prognosis is poor. Novel curative treatment strategies are needed...
  12. ncbi Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1294-302. 2006
    ..In this study, the authors assessed the incidence, presenting characteristics, and outcomes of patients with CLL/SLL who developed Hodgkin lymphoma (HL)...
  13. ncbi Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:373-80. 2009
    ..An 11q22 deletion is considered an independent factor predicting poor survival in chronic lymphocytic leukemia (CLL)...
  14. ncbi Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4648-56. 2007
    ..We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors...
  15. ncbi Relevance of clinical trials in acute myeloid leukaemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    Hematol Oncol 26:182-3. 2008
    ..0001). Our results suggest that newer clinical trials may be less applicable to LLTR patients than previous trials. There is a need for clinical trials specific to the LLTR population, the group most in need of novel therapies...
  16. ncbi Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1370-8. 2008
    ..In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes...
  17. ncbi Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
    Apostolia Maria Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Chemother Pharmacol 65:235-41. 2010
    ..This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling...
  18. ncbi The role of gemtuzumab ozogamicin in acute leukaemia therapy
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 132:398-409. 2006
    ..The future of GO is its use in combination with other cytotoxic agents. Ongoing clinical trials may better define the role of GO combinations, particularly in untreated AML...
  19. ncbi Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial
    Apostolia Maria Tsimberidou
    The University of Texas M D Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:6243-50. 2009
    ..However, several oncology drugs have been approved on the basis of objective end points without a randomized trial. We reviewed the long-term safety and efficacy of such agents...
  20. ncbi Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
    Apostolia Maria Tsimberidou
    Phase 1 Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1507-16. 2011
    ..Midazolam and omeprazole are primarily metabolized by CYP3A4 and CYP2C19, respectively. We evaluated the inhibitory effects of patupilone on the CYP3A4/CYP2C19 pathways...
  21. ncbi Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience
    Apostolia Maria Tsimberidou
    Investigational Cancer Therapeutics and Quantitative Sciences Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 17:4110-8. 2011
    ..Patients with brain metastases are often excluded from clinical trials, but it is unclear whether they pose an enhanced risk...
  22. ncbi Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial
    Apostolia Maria Tsimberidou
    Corresponding Author Apostolia M Tsimberidou, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:209-17. 2011
    ..Patupilone showed antitumor activity in triple-negative breast cancer...
  23. ncbi Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer
    Apostolia Maria Tsimberidou
    Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:3410-9. 2010
    ..3 mg/m(2) once weekly for 3 weeks every 28 days was safe in patients with heavily pretreated cancer. Clinical trials with MPC-6827 and chemotherapy are ongoing...
  24. ncbi Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:247-53. 2011
    ..The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement...
  25. ncbi Ofatumumab in the treatment of chronic lymphocytic leukemia
    A M Tsimberidou
    University of Texas, M D Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Houston, Texas 77030, USA
    Drugs Today (Barc) 46:451-61. 2010
    ..Ofatumumab has significant antileukemic activity and ongoing clinical trials will determine the role of ofatumumab in CLL...
  26. ncbi Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:1188-99. 2010
    ..However, given the diverse mechanisms governing CLL pathogenesis and disease progression, ongoing clinical trials combinations of these agents may improve clinical outcomes for this patient population...
  27. ncbi Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature
    Apostolia Maria Tsimberidou
    Department of Leukemia, UT MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 28:657-60. 2004
    ..It appears that there is no in vivo interaction between imatinib and highly active anti-retroviral therapy (HAART) and these drugs can be concurrently administered with safety to patients with CML and AIDS...
  28. ncbi Richter's transformation in chronic lymphocytic leukemia
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Curr Hematol Malig Rep 2:265-71. 2007
    ..Rituximab and cytotoxic combination therapy followed by stem cell transplantation is associated with improved clinical outcome. Curative treatment strategies are needed...
  29. ncbi Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 66:1087-93. 2010
    ..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement...
  30. ncbi Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma
    Apostolia Maria Tsimberidou
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 27:904-10. 2009
    ..The aim of this study was to determine the frequency, outcomes, and factors associated with other cancers in patients with CLL/SLL...
  31. ncbi Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial
    A H Sarris
    Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Oncol 11:69-72. 2000
    ..We therefore explored its activity in relapsed non-Hodgkin's lymphomas (NHL) and acute lymphoblastic leukemia (ALL)...
  32. ncbi Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome
    A M Tsimberidou
    Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center Houston, Texas 77030, USA
    Leuk Lymphoma 41:535-44. 2001
    ..Since HIV-related deaths exceed those caused by HD, future investigation should focus on integration of chemotherapy and highly active antiretroviral therapy...
  33. ncbi A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:4086-94. 2010
    ..The authors of this report conducted a phase 1 study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases...
  34. ncbi Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
    Leuk Lymphoma 43:767-72. 2002
    ..FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders...
  35. ncbi Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma
    Apostolia M Tsimberidou
    Department of Lymphoma and Myeloma, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
    Blood 100:4351-7. 2002
    ..In conclusion, both regimens were associated with high rates of response and survival. ATT was associated with substantially longer FFS, but it was more toxic than FND...
  36. ncbi Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  37. ncbi PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  38. ncbi Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:997-1005. 2011
    ..We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins...
  39. ncbi Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia
    Jeffrey J Tarrand
    Department of Laboratory Medicine, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 116:880-7. 2010
    ..Epstein-Barr virus (EBV) infection has been associated with Richter transformation in patients with chronic lymphocytic leukemia (CLL)...
  40. ncbi Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT
    John F Bruzzi
    Division of Diagnostic Imaging, M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Nucl Med 47:1267-73. 2006
    ..Our objective was to evaluate the accuracy of PET/CT for the diagnosis of Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma...
  41. ncbi Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
    Francis J Giles
    The University of Texas, M D Anderson Cancer Center, Department of Leukemia, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Leuk Res 29:649-52. 2005
    ..There was no significant impact on CR rates, TTF, survival, or toxicity of adding an IL-11 regimen to IA induction in patients >/=50 years of age with AML...
  42. ncbi Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. CONCLUSIONS: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML...
  43. ncbi Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 50:497-500. 2002
    ..CONCLUSIONS: MTA was moderately effective and associated with significant toxicity in patients with refractory AML...
  44. ncbi Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..CONCLUSIONS: The study regimen had activity and significant toxicity in patients with RS or fludarabine-refractory CLL. It was not clearly better compared with hyper-CVXD alone in this patient population...
  45. ncbi Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone
    Andreas H Sarris
    Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 29:48-55. 2002
    ..The presence of cells with t(14;18) and their numbers are prospectively quantitated in blood and marrow of patients treated with FND plus rituximab to determine their clinical significance both at presentation and during therapy...
  46. ncbi Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience
    J J Wheler
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Oncol 23:1963-7. 2012
    ..This study assessed toxicity in advanced cancer patients treated in a phase I clinic that focuses on targeted agents...
  47. ncbi Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease
    Apostolia M Tsimberidou
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA
    Leuk Lymphoma 44:1719-25. 2003
    ..Human antimouse antibody (HAMA) and/or human antiricin antibody (HARA) development was documented in 2 patients. Anti-B4 blocked ricin was well tolerated but had limited activity in patients with residual CLL after chemotherapy...
  48. ncbi Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2583-91. 2004
    ..Eleven patients (12.5%) developed a second malignancy after a median of 62 months. CONCLUSIONS: The FN regimen did not have a significant advantage over fludarabine alone in the treatment of patients with CLL...
  49. ncbi Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
    Apostolia M Tsimberidou
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, Houston, Texas77030, USA
    Cancer 107:125-35. 2006
    ..The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone...
  50. ncbi The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
    Constantine S Tam
    Department of Leukemia and Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Leuk Lymphoma 48:1931-9. 2007
    ..Overall survival was 9 months, with hemoglobin < 11 g/dL (hazard ratio 2.3), hepatomegaly (hazard ratio 2.4), and performance status > or = 2 (hazard ratio 1.9) being significant independent predictors of inferior survival...
  51. ncbi Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics a Phase 1 Program, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 115:1091-9. 2009
    ....
  52. ncbi Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center
    Qi Liu
    Department of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1582-9. 2006
    ..The apparent plateau in the FFS curve, starting approximately 8 to 10 years from the beginning of treatment, raises the issue of the potential curability of these patients...
  53. ncbi Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience
    Dolly G Aguilera
    Division of Pediatrics, The University of Texas MD Anderson Cancer Center, TX, USA
    J Pediatr Hematol Oncol 31:803-11. 2009
    ..003). Childhood t-MDS/AML has a poor prognosis. Although patients benefited from AML-type induction chemotherapy followed by stem cell transplantation as postremission therapy, effective therapies, and prevention are needed...
  54. ncbi Cardiovascular toxicity profiles of vascular-disrupting agents
    Ishwaria M Subbiah
    Department of Internal Medicine, University of Texas Medical School at Houston, Houston, Texas, USA
    Oncologist 16:1120-30. 2011
    ..Preclinical and early-phase trials have demonstrated the promising therapeutic benefits of VDAs but have also uncovered a distinctive toxicity profile highlighted by cardiovascular events...
  55. ncbi Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 52:229-34. 2003
    ..CONCLUSIONS: The combination of imatinib mesylate and anagrelide was safe and was associated with an 89% CHR rate in patients with CML in chronic phase and persistent thrombocythemia...
  56. ncbi Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Breast Cancer 10:46-51. 2010
    ..Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents...
  57. ncbi Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Christos Vaklavas
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 15:130-41. 2010
    ..Therapies targeting vascular endothelial growth factor (VEGF) are associated with hypertension, cardiotoxicity, and thromboembolic events...
  58. ncbi Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia
    Apostolia Maria Tsimberidou
    Department of Internal Medicine, The University of Athens, Athens 11527, Greece
    Leuk Res 26:143-54. 2002
    ..These results suggest that MDR transporter-proteins have a limited role in the treatment failure of patients treated with Idarubicin-based regimens...
  59. ncbi Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment
    Apostolia Maria Tsimberidou
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:375-80. 2003
    ..No objective response occurred. Acceleration of disease occurred in four patients. While well-tolerated, Enbrel did not have anti-myeloma activity as administered on this study...